To the Editor: I wish to point out an error in the excellent review of MAO inhibitors published in the December 2010 issue of the Cleveland Clinic Journal of Medicine . The authors state, “The only selective MAO inhibitor now available in the United States is selegiline, which inhibits MAO-B at low doses but loses its selectivity at dosages greater than 20 mg/day” (on page 861). In fact, a second selective MAO inhibitor has been available in the United States for several years. Rasagiline, developed by Teva Pharmaceuticals and marketed under the brand name Azilect, is a highly selective MAO-B inhibitor indicated for treating the symptoms of Parkinson disease, either as monotherapy or as adjunct therapy to carbidopa-levodopa. However, rasagiline is not indicated for the treatment of depression. Perhaps the authors meant to say that selegiline is the only selective MAO-B inhibitor indicated for treating depression in the United States.
Letters To The Editor
Cleveland Clinic Journal of Medicine. 2011 February;78(2):81
David Keller, MD
Current Drug Therapy
- Molly Wimbiscus, MD
- Olga Kostenko, MD
- Donald Malone, MD
Monoamine oxidase inhibitors were the first antidepressants introduced. Interest in their use if reviving.